David Reid Cornblath

David Reid Cornblath's AcademicInfluence.com Rankings

Biology

#6414

World Rank

#9119

Historical Rank

Neuroscience

#777

World Rank

#810

Historical Rank

biology Degrees

Download Badge

Biology

David Reid Cornblath's Degrees

Bachelors Neuroscience University of Maryland, College Park
Masters Neuroscience Johns Hopkins University

Why Is David Reid Cornblath Influential?

(Suggest an Edit or Addition)

(See a Problem?)

David Reid Cornblath's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Assessment of current diagnostic criteria for Guillain‐Barré syndrome (1990) (1821)
Guillain-Barré syndrome (1994) (1073)
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First Revision (2010) (1059)
Peripheral neuropathy. (1982) (1016)
Electrophysiological classification of guillain‐barré syndrome: Clinical associations and outcome (1998) (849)
DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4). (2004) (793)
Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus‐type 1 (HIV‐1) infection (1991) (773)
Guillain-Barré syndrome in northern China. Relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. (1995) (730)
The spectrum of neuropathy in diabetes and impaired glucose tolerance (2003) (682)
Abnormal excitatory amino acid metabolism in amyotrophic lateral sclerosis (1990) (646)
Acute motor axonal neuropathy: A frequent cause of acute flaccid paralysis in China (1993) (630)
A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside (1988) (603)
Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients (2005) (550)
Double‐blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy (1998) (539)
Epidermal nerve fiber density: normative reference range and diagnostic efficiency. (1998) (528)
Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. (2011) (504)
Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia. (2016) (494)
Acute motor axonal neuropathy: An antibody‐mediated attack on axolemma (1996) (478)
A framework for diagnosing and classifying intensive care unit-acquired weakness. (2009) (471)
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society – First Revision (2010) (467)
EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy (2005) (435)
European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of multifocal motor neuropathy. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision (2010) (410)
Pathology of the motor‐sensory axonal Guillain‐Barré syndrome (1996) (409)
Immune attack on the schwann cell surface in acute inflammatory demyelinating polyneuropathy (1996) (399)
Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome (1990) (397)
The effect of systemically administered recombinant human nerve growth factor in healthy human subjects (1994) (391)
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society (2006) (370)
Preceding infections, immune factors, and outcome in Guillain–Barré syndrome (2001) (369)
Diagnosis and management of Guillain–Barré syndrome in ten steps (2019) (357)
Guillain-Barré syndrome in northern China. The spectrum of neuropathological changes in clinically defined cases. (1995) (356)
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies (1994) (352)
Quantitative sensory testing (2003) (350)
HIV‐Associated Disease of the Nervous System: Review of Nomenclature and Proposal for Neuropathology‐Based Terminology (1991) (335)
Cutaneous innervation in sensory neuropathies (1995) (332)
Inflammatory demyelinating peripheral neuropathies associated with human T‐cell lymphotropic virus type III infection (1987) (332)
Small‐fiber sensory neuropathies: Clinical course and neuropathology of idiopathic cases (1998) (326)
Anti‐GD1a antibody is associated with axonal but not demyelinating forms of Guillain‐Barré syndrome (1999) (305)
Tramadol for neuropathic pain. (2006) (301)
Intraepidermal nerve fiber density in patients with painful sensory neuropathy (1997) (298)
Predominantly sensory neuropathy in patients with AIDS and AIDS‐related complex (1988) (294)
Low prevalence of neurological and neuropsychological abnormalities in otherwise healthy HIV‐1–infected individuals: Results from the multicenter AIDS cohort study (1989) (285)
European Federation of Neurological Societies/Peripheral Nerve Society Guideline * on management of paraproteinemic demyelinating neuropathies. Report of a Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society – first revision (2010) (285)
Serum antibodies to gangliosides in guillain‐barré syndrome (1988) (282)
Total neuropathy score (1999) (277)
Practice parameter: Immunotherapy for Guillain–Barré syndrome (2003) (268)
Plasmapheresis and guillain‐barré syndrome: Analysis of prognostic factors and the effect of plasmapheresis (1988) (262)
Lower motor neuron syndromes defined by patterns of weakness, nerve conduction abnormalities, and high titers of antiglycolipid antibodies (1990) (261)
Epidermal nerve fiber density and sural nerve morphometry in peripheral neuropathies (1999) (261)
Clinical and electrophysiological aspects of acute paralytic disease of children and young adults in northern China (1991) (261)
Supportive care for patients with Guillain-Barré syndrome. (2005) (258)
Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain-Barré syndrome (1996) (258)
Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases (2001) (255)
Guillain-Barré syndrome: An update (2009) (246)
Evidence-based guideline update: Plasmapheresis in neurologic disorders (2011) (237)
Multifocal motor neuropathy: Response to human immune globulin (1993) (225)
Neurotoxicity of Taxol. (1993) (222)
Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34. (1998) (214)
European Federation of Neurological Societies/Peripheral Nerve Society Guideline * on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society (2005) (211)
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. (2013) (202)
Wallerian degeneration in human nerves: Serial electrophysiological studies (1992) (200)
Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after campylobacter infection (1997) (194)
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. (1993) (194)
Nerve conduction studies in amyotrophic lateral sclerosis (1992) (191)
Maintenance of the long-term effectiveness of tramadol in treatment of the pain of diabetic neuropathy. (2000) (182)
Thalidomide-induced neuropathy (2002) (177)
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial (2018) (176)
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of multifocal motor neuropathy * (2006) (176)
Motor conduction studies in guillain‐barré syndrome: Description and prognostic value (1988) (170)
Patterns of recovery in the Guillain-Barre syndromes (1997) (169)
Cerebrospinal fluid abnormalities in homosexual men with and without neuropsychiatric findings (1988) (169)
Epidermal innervation: changes with aging, topographic location, and in sensory neuropathy (1999) (169)
Conduction block in clinical practice (1991) (166)
Modifying the Medical Research Council grading system through Rasch analyses (2011) (165)
Characteristics of bortezomib‐ and thalidomide‐induced peripheral neuropathy (2008) (163)
Characterization of the gene encoding human sarcolipin (SLN), a proteolipid associated with SERCA1: absence of structural mutations in five patients with Brody disease. (1997) (162)
Polyneuropathy syndromes associated with serum antibodies to sulfatide and myelin‐associated glycoprotein (1991) (161)
Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study (2009) (156)
Regional variation of Guillain-Barré syndrome (2018) (156)
Regional variation of Guillain-Barré syndrome (2018) (156)
Campylobacter jejuni lipopolysaccharides in Guillain-Barré syndrome (1998) (153)
Novel mutations in families with unusual and variable disorders of the skeletal muscle sodium channel (1992) (146)
Serum antibodies to GM1 ganglioside in amyotrophic lateral sclerosis (1988) (145)
Neopterin and interferon‐gamma in serum and cerebrospinal fluid of patients with HIV‐associated neurologic disease (1991) (137)
Physician-assessed and patient-reported outcome measures in chemotherapy-induced sensory peripheral neurotoxicity: two sides of the same coin. (2014) (126)
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision (2021) (126)
Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy (2009) (125)
Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin (1991) (121)
NEUROPHYSIOLOGICAL AND NEUROPSYCHOLOGICAL FUNCTION IN MERCURY-EXPOSED DENTISTS (1982) (120)
Intensive management and treatment of severe Guillain‐Barré syndrome (1993) (116)
A new dietary therapy for adrenoleukodystrophy: Biochemical and preliminary clinical results in 36 patients (1987) (114)
Multifocal motor neuropathy: Electrodiagnostic features (1994) (113)
Inter‐ and intra‐examiner reliability of nerve conduction measurements in normal subjects (1991) (111)
Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy (2019) (108)
Gracile tract degeneration in patients with sensory neuropathy and AIDS (1988) (106)
Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice (2010) (104)
Azathioprine in the treatment of myasthenia gravis (1984) (104)
Clinical electrophysiology of infantile botulism (1983) (104)
Relapse in Guillain‐Barré syndrome after treatment with human immune globulin (1993) (103)
Patterns of serum IgM antibodies to GM1 and GD1a gangliosides in amyotrophic lateral sclerosis (1989) (103)
Autosomal dominant juvenile amyotrophic lateral sclerosis. (1999) (102)
Peripheral neuropathy in Parkinson's disease: levodopa exposure and implications for duodenal delivery. (2013) (100)
Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation (1994) (97)
A prospective study of suramin-induced peripheral neuropathy. (1996) (95)
Neuropathological alterations in diabetic truncal neuropathy: evaluation by skin biopsy (1998) (94)
A β‐subunit mutation in the acetylcholine receptor channel gate causes severe slow‐channel syndrome (1996) (94)
Excitatory amino acids in amyotrophic lateral sclerosis: An update (1991) (93)
Autonomic and peripheral (sensorimotor) neuropathy in chronic liver disease: A clinical and electrophysiologic study (1999) (92)
Assessment of thoracic paraspinal muscles in the diagnosis of ALS (1988) (90)
Electrophysiological studies in the Guillain–Barré syndrome: Distinguishing subtypes by published criteria (1998) (86)
Sensory nerve pathology in multifocal motor neuropathy (1996) (86)
Electrophysiology in Gullian‐Barré syndeome (1990) (86)
Head drop and camptocormia (2002) (85)
Measures of chemotherapy‐induced peripheral neuropathy: a systematic review of psychometric properties (2010) (83)
International Guillain‐Barré Syndrome Outcome Study: protocol of a prospective observational cohort study on clinical and biological predictors of disease course and outcome in Guillain‐Barré syndrome (2017) (79)
Dominant GDAP1 mutations cause predominantly mild CMT phenotypes (2011) (78)
Differentiating lower motor neuron syndromes (2016) (78)
Low-dose zalcitabine-related toxic neuropathy (1996) (78)
Diagnosis and Management of Peripheral Nerve Disorders (2001) (77)
Macrophage responses in inflammatory demyelinating neuropathies (1990) (77)
Quantitative analysis of endoneurial T-cells in human sural nerve biopsies (1990) (76)
Neuropathological changes in early HIV‐1 dementia (1989) (74)
COVID-19 vaccine and Guillain-Barré syndrome: let’s not leap to associations (2020) (74)
Human immunodeficiency virus (HIV) infection and the nervous system (1989) (73)
Characterization of cDNA and genomic DNA encoding SERCA1, the Ca(2+)-ATPase of human fast-twitch skeletal muscle sarcoplasmic reticulum, and its elimination as a candidate gene for Brody disease. (1995) (73)
Patterns of Guillain-Barré syndrome in children (2007) (73)
Congenital end-plate acetylcholinesterase deficiency caused by a nonsense mutation and an A-->G splice-donor-site mutation at position +3 of the collagenlike-tail-subunit gene (COLQ): how does G at position +3 result in aberrant splicing? (1999) (73)
Electrophysiology in Guillain-Barré syndrome. (1997) (72)
Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. (1996) (71)
European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society * (2006) (70)
Physiologic-pathologic correlation in Guillain–Barré syndrome in children (2000) (67)
Clinical applications of intravenous immunoglobulins in neurology (2009) (66)
Recent advances in HIV neuropathy (2006) (66)
European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second revision (2021) (65)
Anti-GM1 ganglioside antibodies with differing fine specificities in patients with multifocal motor neuropathy (1989) (64)
High‐titer selective serum anti‐β‐tubulin antibodies in chronic inflammatory demyelinating polyneuropathy (1993) (63)
All that palsies is not Bell's -the need to define Bell's palsy as an adverse event following immunization. (2007) (63)
Nerve conduction studies in adrenomyeloneuropathy. (1996) (62)
Treatment of the neuromuscular complications of human immunodeficiency virus infection (1988) (60)
Inter‐ and intraexaminer reliability of nerve conduction measurements in patients with diabetic neuropathy (1994) (59)
An open‐label trial of rituximab (Rituxan®) in multifocal motor neuropathy (2010) (56)
Changing outcome in inflammatory neuropathies (2014) (55)
Chronic demyelinating polyneuropathy in systemic lupus erythematosus (1984) (54)
Molecular Mimicry in Guillain‐Barré Syndrome a (1998) (49)
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. (2013) (49)
The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. (2013) (49)
Neurophysiological, nerve imaging and other techniques to assess chemotherapy-induced peripheral neurotoxicity in the clinical and research settings (2019) (48)
Current treatment practice of Guillain-Barré syndrome (2019) (47)
Paramyotonia congenita or hyperkalemic periodic paralysis? Clinical and electrophysiological features of each entity in one family (1990) (46)
HIV‐1 infection and nervous system abnormalities among a cohort of intravenous drug users (1991) (45)
Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial (2018) (43)
A dominant mutation in FBXO38 causes distal spinal muscular atrophy with calf predominance. (2013) (43)
Conduction block in neuropathies with necrotizing vasculitis. (1991) (43)
Monitoring azathioprine therapy in myasthenia gravis (1986) (42)
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). (2013) (42)
Correspondence between neurophysiological and clinical measurements of chemotherapy‐induced peripheral neuropathy: secondary analysis of data from the CI‐PeriNomS study (2014) (41)
Effect of MRI on treatment results or decision making in patients with lumbosacral radiculopathy referred for epidural steroid injections: a multicenter, randomized controlled trial. (2012) (41)
Differential effects of prednisone and cyclophosphamide on autoantibodies in human neuromuscular disorders (1989) (40)
A gene for autosomal dominant juvenile amyotrophic lateral sclerosis (ALS4 ) localizes to a 500-kb interval on chromosome 9q34 (2000) (40)
Transient conduction block following acute peripheral nerve ischemia (1985) (40)
Surgical Decompression for Diabetic Sensorimotor Polyneuropathy (2007) (40)
Conduction block in diabetic neuropathy (1991) (39)
Compression syndromes due to hypertrophic nerve roots in hereditary motor sensory neuropathy type I (1989) (39)
Identification of mononuclear cells in CSF of patients with HIV infection (1989) (38)
Vestibular dysfunction in chronic inflammatory demyelinating Polyneuropathy (1996) (37)
Campylobacter serology in patients with Chinese paralytic syndrome (1991) (37)
Peripheral neuropathies in human immunodeficiency virus infection. (2004) (36)
Therapeutic plasma exchange in neurology: 2012 (2013) (36)
DIABETIC NEUROPATHY: DIAGNOSTIC METHODS — (2004) (35)
Second IVIg course in Guillain‐Barré syndrome patients with poor prognosis (SID‐GBS trial): Protocol for a double‐blind randomized, placebo‐controlled clinical trial (2018) (35)
Axoplasmic flow in cerebellar mossy and climbing fibers. (1973) (35)
Anti-GD 1 a Antibody Is Associated with Axonal But Not Demyelinating Forms of Guillain-Barré Syndrome (1999) (34)
Influence of malnutrition on developing rat peripheral nerves (1988) (34)
Soluble interleukin-2 receptor and soluble CD8 in serum and cerebrospinal fluid during human immunodeficiency virus-associated neurologic disease (1990) (32)
Facial nerve palsy including Bell's palsy: Case definitions and guidelines for collection, analysis, and presentation of immunisation safety data. (2017) (32)
Electrodiagnosis of human colchicine myoneuropathy (1989) (32)
Grip strength comparison in immune‐mediated neuropathies: Vigorimeter vs. Jamar (2015) (30)
Open muscle biopsy in suspected myopathy: diagnostic yield and clinical utility (2010) (29)
Original research: Second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study (2019) (29)
Creutzfeldt‐Jakob disease in a 20‐year‐old woman (1980) (28)
Impairment measures versus inflammatory RODS in GBS and CIDP: a responsiveness comparison (2015) (28)
Correlation of the patient's reported outcome Inflammatory‐RODS with an objective metric in immune‐mediated neuropathies (2016) (28)
Guillain-Barré Syndrome in India: population-based validation of the Brighton criteria. (2011) (28)
The safety profile of dalfampridine extended release in multiple sclerosis clinical trials. (2012) (27)
Comparing the NIS vs. MRC and INCAT sensory scale through Rasch analyses (2015) (27)
Tolerability of recombinant‐methionyl human neurotrophin‐3 (r‐metHuNT3) in healthy subjects (2000) (26)
Guillain-Barré syndrome in the 100 years since its description by Guillain, Barré and Strohl. (2016) (26)
Bortezomib and Thalidomide Treatment of Newly Diagnosed Patients with Multiple Myeloma - Efficacy and Neurotoxicity. (2006) (25)
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial (2016) (25)
Role of therapeutic plasmapheresis in the acute Guillain-Barré syndrome (1988) (25)
Steroid‐responsive myeloneuropathy in a man dually infected with HIV‐1 and HTLV‐I (1990) (24)
Observations on chronic inflammatory demyelinating polyneuropathy: A plea for a rigorous approach to diagnosis and treatment (2013) (24)
Manipulating the immune system with immune globulin. (1992) (23)
Rasch‐Transformed Total Neuropathy Score clinical version (RT‐TNSc©) in patients with chemotherapy‐induced peripheral neuropathy (2015) (23)
Disorders of neuromuscular transmission in infants and children (1986) (22)
Erratum: A β-subunit mutation in the acetylcholine receptor channel gate causes severe slow-channel syndrome (Annals of Neurology (1996) 39 (712- 723)) (1996) (22)
Stretch palsy of the spinal accessory nerve. Case report. (1990) (22)
Stimulated single‐fiber electromyography in lambert‐eaton myasthenic syndrome (1991) (22)
Rapid worsening of IgM anti‐MAG demyelinating polyneuropathy during rituximab treatment (2013) (22)
Worsening of multifocal motor neuropathy during pregnancy (2002) (21)
Pain in chemotherapy‐induced peripheral neurotoxicity (2017) (21)
Poliomyelitis and flaviviruses (2003) (20)
Peripheral Neuropathy in Diabetic Monkeys (1989) (19)
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP: PATH extension study. (2019) (18)
Patients' and physicians' interpretation of chemotherapy‐induced peripheral neurotoxicity (2019) (18)
National Institute of Neurological Disorders and Stroke (NINDS): Advances in understanding and treating neuropathy, 24–25 October 2006; Bethesda, Maryland (2008) (17)
Molecular insight into the asymmetric distribution of pathogenetic human mitochondrial DNA deletions. (1991) (17)
Chapter 22 Peripheral neuropathies in human immunodeficiency virus infection (2004) (16)
Spontaneous diabetes mellitus in a rhesus monkey: Neurophysiological studies (1989) (16)
Guillain-Barré Syndrome Outbreak in Peru 2019 Associated With Campylobacter jejuni Infection (2021) (16)
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial (2021) (15)
Laboratory testing in peripheral nerve disease. (1996) (15)
Does ability to walk reflect general functionality in inflammatory neuropathies? (2016) (15)
Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial (2021) (15)
Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies (2019) (15)
Autosomal dominant distal spinal muscular atrophy in four generations (1995) (14)
Early invasive CNS aspergillosis. An easily missed diagnosis. (1991) (14)
Early invasive CNS aspergillosis (2004) (14)
Long-term safety and efficacy of subcutaneous immunoglobulin IgPro20 in CIDP (2019) (14)
Clinical and genetic description of a family with Charcot–Marie–Tooth disease type 1B from a transmembrane MPZ mutation (2004) (13)
Alpha‐lipoic acid for diabetic peripheral neuropathy (2005) (13)
Placebo effect in chronic inflammatory demyelinating polyneuropathy: The PATH study and a systematic review (2020) (13)
Acetylcholine epilepsy: Relationship of surface concentration, chronicity of denervation, and focus size (1975) (12)
Distribution of radioactivity from topically applied [H3]acetylcholine in relation to seizure (1976) (12)
Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study (2019) (12)
Toxic neuropathies: chemotherapy-induced peripheral neurotoxicity. (2019) (12)
Conjugal amyotrophic lateral sclerosis (1993) (12)
A randomised, multi‐centre phase III study of 3 different doses of intravenous immunoglobulin 10% in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ProCID trial): Study design and protocol (2018) (11)
Paraproteinaemic Demyelinating Neuropathies (2010) (11)
Patient‐reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study (2020) (11)
IgPro20, the Polyneuropathy and Treatment with Hizentra® study (PATH), and the treatment of chronic inflammatory demyelinating polyradiculoneuropathy with subcutaneous IgG. (2018) (10)
Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy-Induced Peripheral Neurotoxicity (2021) (10)
231st ENMC International Workshop: International Standard for CIDP Registry and Biobank, Naarden, The Netherlands, 12–14 May 2017 (2017) (10)
Immunoreactive myelin basic protein in cerebrospinal fluid of patients with peripheral neuropathies (1986) (10)
Acetylcholine epilepsy: modification of DC shift in chronically undercut cat cortex. (1974) (10)
Boundaries of chronic inflammatory demyelinating polyradiculoneuropathy (2020) (10)
Werdnig‐Hoffmann disease and chronic distal spinal muscular atrophy with apparent autosomal dominant inheritance (1992) (10)
APOE ε4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy (2005) (9)
Neuroviruses Emerging in the Americas Study (NEAS): The Colombian experience during the 2016 outbreak of Zika virus infection (N4.002) (2017) (8)
APOE epsilon4 is not a susceptibility gene in idiopathic or diabetic sensory neuropathy. (2005) (8)
Chronic inflammatory demyelinating polyneuropathy and paraproteinemic neuropathies (1994) (8)
Treatment for guillain‐barré syndrome (2009) (8)
Guillain-Barré syndrome – Authors' reply (2006) (8)
230th ENMC International Workshop: Improving future assessment and research in IgM anti-MAG peripheral neuropathy: A consensus collaborative effort, Naarden, The Netherlands, 24–26 February 2017 (2017) (7)
Mononuclear cell typing in inflammatory demyelinating polyneuropathy nerve biopsies (1987) (7)
Perioperative bilateral median neuropathy. (2002) (7)
Peripheral Nerve Vasculitis Presenting as Complex Regional Pain Syndrome (2008) (7)
Yield of next‐generation neuropathy gene panels in axonal neuropathies (2019) (6)
Peripheral neuropathies in human immunodeficiency virus type 1 infection (1995) (6)
A novel HSPB1 mutation associated with a late onset CMT2 phenotype: Case presentation and systematic review of the literature (2020) (6)
Guillain-Barré syndrome in times of pandemics (2020) (6)
Peroxisomal disorders. (1991) (6)
Incidence of irritable electromyography in inflammatory myopathy. (1999) (6)
Gomez, C. M. et al. A -subunit mutation in the acetylcholine receptor gate causes severe slow-channel syndrome. Ann. Neurol. 39, 712-723 (1996) (5)
Skin biopsy and small fibre neuropathies: facts and thoughts 30 years later (2022) (5)
Nerve conduction studies in diabetic neuropathy (1995) (5)
Chronic demyelinating polyneuropathy associated with eosinophilia-myalgia syndrome. (1992) (5)
Intact Bell's phenomenon in a patient with myasthenia gravis and upward gaze paresis. (1989) (4)
Response to comment on European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy (2006) (4)
Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), a multicenter randomized double-blind placebo-controlled trial: the Path study (2017) (4)
The electrophysiology of axonal and demyelinating polyneuropathies. (1996) (4)
GUILLAIN-BARRE SYNDROME IN NORTHERN CHINA. THE SPECTRUM OF NEUROPATHOLOGICAL CHANGES IN CLINICALLY DEFINED CASES. AUTHORS'S REPLIES (1996) (4)
Randomized trial of three IVIg doses for treating chronic inflammatory demyelinating polyneuropathy (2022) (3)
The value of rectus abdominal muscle electromyography. (1987) (3)
Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values (2022) (3)
Treatment for human immunodeficiency virus-related distal symmetrical polyneuropathy (2003) (3)
Chapter 34 Guillain-Barré syndrome (2006) (3)
An International Perspective on Preceding Infections in Guillain-Barré Syndrome (2022) (3)
Chapter 25. Paraproteinaemic Demyelinating Neuropathy (2008) (3)
Electrodiagnosis of Guillain-Barre syndrome in the International GBS Outcome Study: Differences in methods and reference values (2022) (3)
Chemotherapy‐induced peripheral neurotoxicity: Facts, needs and future directions (2019) (2)
Inflammatory demyelinating polyneuropathies in human immunodeficiency virus infection (1986) (2)
Meeting Report: 2013 Peripheral Nerve Society Biennial Meeting, Saint‐Malo, France, June 29–July 3, 2013 (2013) (2)
X-linked adrenoleukodystrophy: Epidemiology, pathogenesis and therapy (1990) (2)
A recurrent MORC2 mutation causes Charcot‐Marie‐Tooth disease type 2Z (2021) (2)
Creutzfeldt‐Jakob disease in a 20‐year‐old woman (1981) (2)
Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study (2021) (2)
Fatigue in chronic inflammatory demyelinating polyradiculoneuropathy (2020) (2)
Neuropathy in grout workers (2004) (2)
The Guillain-Barré syndrome and human immunodeficiency virus. (1989) (2)
Quantitative sensory testing Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (2003) (1)
Clinical electromyography: 2nd edn. - William F. Brown and Charles F. Bolton (Eds.) (Heinemann, Boston, 1993, 810pp., Price: US $150.00) (1997) (1)
Subacute sensory neuronopathy and cancer: the identification of paraneoplastic syndromes (2020) (1)
[Evidence based guidelines. Diagnosis and management of Guillain-Barré syndrome in ten steps]. (2021) (1)
Feasibility of switching from intravenous to subcutaneous immunoglobulin in CIDP: PATH trial and clinical experience (2019) (1)
The Jack Griffin Memorial Symposium. (2012) (1)
Electrodiagnostic subtyping in Guillain‐Barré syndrome: Use of criteria in practice based on a survey study in IGOS (2022) (1)
Guillain-Barré syndrome: the evolution of therapy (1994) (1)
Electrophysiological Testing in Patients with Chronic Inflammatory Demyelinating Polyneuropathy Treated with Subcutaneous Immunoglobulin: The PATH Study (P1.433) (2018) (1)
DS3.1 Neuromuscular manifestations of HIV infection (2006) (1)
Pharmacometric analysis linking immunoglobulin exposure to clinical efficacy outcomes in chronic inflammatory demyelinating polyneuropathy (2021) (1)
Letter from new Editor‐in‐Chief (2007) (1)
Peripheral nerve and spinal cord disease in human retrovirus infections (1990) (1)
Abnormal nerve function in dentists with elevated tissue mercury levels (1982) (1)
Plenary I : How Do We Measure Up ? Quantitation in EDX and Clinical Practice (2012) (1)
Comment on research report by Gruson and colleagues, this issue (2011) (0)
IVIG: Effective Treatment for Sensory Neuronopathy in Sjögren's? (2003) (0)
77. Bortezomib and thalidomide-induced subacute demyelinating polyneuropathy (2009) (0)
Subcutaneous immunoglobulin (SCIG) for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (CIDP), a multicenter randomized double-blind placebo-controlled trial: The PATH Study (2019) (0)
Abstracts of the 2008 Inflammatory Neuropathy Consortium (INC) Meeting (2008) (0)
Cerebrospinal Fluid Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome. (2023) (0)
20. Practical application of subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy – results from a multicenter, randomized, double-blind, placebo-controlled trial (The PATH Study) (2020) (0)
IN71-FR-01 Multifocal motor neuropathy (2009) (0)
Wireless, Bedside, Patient Outcomes Data Collection Obtained During Home Infusions (CareExchange TM ) (2012) (0)
Intravenous human immune globulin in Guillain-Barré syndrome (1997) (0)
Demylinating Peripheral Neuropathy and Lymphoplasmacytic Lymphoma (2010) (0)
Letter to the Editor re "Complete Foot Drop With Normal Electrodiagnostic Studies: Sunderland 'Zero' Ischemic Conduction Block of the Common Peroneal Nerve" by Peters and Colleagues. (2022) (0)
Erratum: Linkage of the gene for an autosomal dominant form of juvenile amyotrophic lateral sclerosis to chromosome 9q34 (American Journal of Human Genetics (March) 62 (633-640)) (1998) (0)
21. Exposure-response of serum IgG levels and INCAT scores in CIDP patients receiving subcutaneous immunoglobulin (IgPro20) (2020) (0)
Peripheral nerve safety measures in a multicenter, double-blind, randomized, placebo-controlled, dose-ranging study of fulranumab in patients with painful diabetic neuropathy (2013) (0)
A 68-year-old man with diabetic peripheral neuropathy (2004) (0)
Reply (1998) (0)
19. Pharmacokinetic modelling and simulation of flexible dosing regimens of subcutaneous immunoglobulin (IgPro20) in CIDP patients (2020) (0)
Panel discussion of case study 1 (2005) (0)
046 Efficacy and safety of intravenous immunoglobulin (IVIG) IGPRO10 in chronic inflammatory demyelinating polyneuropathy (CIDP) (2018) (0)
Format for case reports of known CMT genes that merit reporting (2010) (0)
PATH (polyneuropathy and treatment with Hizentra ®: a randomized, controlled trial of Hizentra ®, a 20% immunoglobulin preparation for subcutaneous administration, in patients with chronic inflammatory demyelinating polyradiculoneuropathy (2012) (0)
JAMA Neurology Peer Reviewers in 2017. (2018) (0)
Inflammatory Neuropathy Consortium: Report of a meeting held on 4–6 July 2008, Bâtiment Babinski, Hôpital de la Salpêtrière, Paris, France (2008) (0)
Reply (1993) (0)
Creutzfeldt‐Jakob disease in a 20‐year‐old woman (1981) (0)
IgM Anti MAG± Peripheral Neuropathy (IMAGiNe) Study Protocol: An international, observational, prospective registry of patients with IgM M-protein Peripheral Neuropathies. (2023) (0)
Conduction Abnormalities in ALS and in Diabetes Differ (2002) (0)
Efficacy and safety of intravenous immunoglobulin IgPro10 in CIDP: Combination of PRIMA and PATH studies (2018) (0)
Featured Cover (2021) (0)
Principles of Immunomodulatory Therapy (1994) (0)
Reply (1996) (0)
Report from the Satellite Meeting of the Peripheral Nerve Society in Sydney, Australia, July 5–7, 2010 (2010) (0)
Chapter 15 Principles of Immunomodulatory Therapy (1994) (0)
Analysis of relapse by inflammatory Rasch‐built overall disability scale status in the PATH study of subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy (2022) (0)
2007 impact factor for the Journal of the Peripheral Nervous System: 2.943 (2008) (0)
Books Received (2001) (0)
Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II–IV ovarian cancer: Japanese Gynecologic Oncology Group Trial (JGOG3016) (2013) (0)
Into Mechanisms Causing Neuronal Dysfunction and Death. It Diagnosis and Management of Peripheral Nerve Disorders Edited (0)
S-3-3 Multifocal motor neuropathy: reflections over 7 years (1995) (0)
Erratum: Rasch-built Overall Disability Scale for Multifocal motor neuropathy (MMN-RODS©) (Journal of the Peripheral Nervous System (2015) 20 (296-305)) (2016) (0)
Supplementary tables/figures and referecences to A Prospective Evaluation of Health Care Provider and Patient Assessments in Chemotherapy Induced Peripheral Neurotoxicity. (2021) (0)
Intravenous versus subcutaneous immunoglobulin – Authors' reply (2018) (0)
Guillain-Barré Syndrome with an Atypical Course (2010) (0)
18. Secondary endpoints (PATH extension study): Long-term outcomes of subcutaneous immunoglobulin IgPro20 in CIDP maintenance treatment (2020) (0)
A Phase 2/3 Placebo-Controlled, Parallel Group, Randomized Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: the ARISE study (P14-8.006) (2023) (0)
A recurrent MORC2 mutation causes CMT2Z. (2021) (0)
Letters to the editor (1991) (0)
JAMA Neurology Peer Reviewers in 2017. (2018) (0)
THE INFLAMMATORY NEUROPATHY CONSORTIUM REGISTRY FOR MULTIFOCAL MOTOR NEUROPATHY (2011) (0)
Introduction (2012) (0)
P33 - The design of a phase III trial to confirm efficacy and safety of PXT3003 for the treatment of Charcot-Marie-Tooth Disease Type 1A (2015) (0)
Reply (1991) (0)
Letters to the editor (1987) (0)
Provider Perceptions Of Clinical Neuropathy Examination Usefulness (2013) (0)
PLASMA EXCHANGE IN GUILLAIN-BARRE SYNDROME AND CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (1996) (0)
17. Benefit-Risk Profile of Intravenous Immunoglobulin (IVIG) and Subcutaneous Immunoglobulin (SCIG) in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): The PATH study (2020) (0)
Suramin-induced demyelinating neuropathy (1996) (0)
BS7 Demyelinating peripheral neuropathy (2006) (0)
Efficacy and Safety of Intravenous Immunoglobulin (IVIG) IgPro10 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): the PRIMA and PATH studies (P1.153) (2018) (0)
Reply (1994) (0)
Clinical applications of neurotropic factors. Edited by Stuart Apfel, Philadelphia, Lippincott‐Raven, 1997 209 pp, illustrated $95.00 (1998) (0)
Academy of disorders : Report of the Therapeutics and Technology Evidence-based guideline update : Plasmapheresis in neurologic (2011) (0)
CURRENT DIAGNOSTIC CRITERIA FOR GUILLAIN-BARRE SYNDROME. AUTHRO'S REPLY (1991) (0)
Chapter 24. Multifocal Motor Neuropathy (2008) (0)
Maybe myopathic EMG but not myopathy (2021) (0)
DIFFERENT PATTERNS OF PNS DEMYELINATION OCCUR IN HIV INFECTION: 242 (1989) (0)
Chapter 23. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2008) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With David Reid Cornblath?

David Reid Cornblath is affiliated with the following schools:

Johns Hopkins University